Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Mannitol may cut intradialytic hypotension episodes in patients initiating haemodialysis

21 Oct 2019

Treatment with mannitol does not appear to have superior effects on intradialytic systolic blood pressure (SBP) decline compared with saline solution in acute or chronic kidney disease patients initiating haemodialysis, although the former reduces the frequency of intradialytic hypotension (IDH) episodes, according to the results of a trial.

A total of 52 patients requiring initiation of haemodialysis for acute or chronic kidney disease were randomized to receive mannitol 0.25 g/kg/h (n=25; mean age, 53.4 years; 48 percent male) or placebo (similar volume of 0.9% saline solution; n=27; mean age, 57.7 years; 52 percent male) during the first three dialysis sessions.

The primary endpoint of average decline in SBP did not significantly differ between the mannitol and placebo groups (mean, 15 vs 19 mm Hg, respectively; p=0.3).

On the other hand, the secondary endpoint of the proportion of total sessions complicated by IDH (defined as a decrease of ≥20 mm Hg from the predialysis SBP) was substantially lower in the mannitol group (25 percent vs 43 percent). The drug conferred a nominally lower risk for developing an episode of IDH (odds ratio, 0.38, 95 percent CI, 0.14–1.00), although this finding was of borderline statistical significance (p=0.05).

There were no consistent differences in cardiac and kidney injury biomarker levels between the two treatment groups.

Mannitol was safe and well tolerated compared with placebo, and there were no major issues encountered in terms of protocol feasibility.

Despite the study’s modest sample size and number of events, the findings provide a rationale to design larger multicentre studies using hypertonic mannitol, perhaps with a longer intervention period, to minimize the frequency of intradialytic hypotension, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.